MetaVia maintains a pre-revenue status with zero sales reported over the last ten quarters, while operating losses reached a peak of $10.1 million in 2024Q2 due to intensive R&D spending.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 15K | 19K | 24K | 7K | 28K | 72K | 67K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -15K | -19K | -24K | -7K | -28K | -72K | -67K | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 20.83% | -242.86% | 75% | 61.11% | -7.46% | - | - | - | - | - | - | - |
| Operating Expenses | 13.83M | 13.69M | 28.81M | 15.89M | 19.63M | 15.3M | 29.72M | 20.18M | 15.49M | 33.12M | 14.7M | 8.08M | 266K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 7.26M | 6.89M | 7.26M | 6.73M | 8.64M | 8.75M | 7.85M | 2.7M | 1.6M | 10.44M | 5.96M | 3.18M | 214K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 6.58M | 6.8M | 21.53M | 9.16M | 2.78M | 6.55M | 21.87M | 17.48M | 13.88M | 22.69M | 8.74M | 3.99M | 52K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 24K | 0 | 8.21M | 0 | 0 | 0 | 0 | 0 | 0 | 908K | 0 |
| Operating Income | -13.85M | -13.71M | -28.81M | -15.89M | -19.63M | -15.3M | -29.72M | -20.18M | -15.49M | -33.12M | -14.7M | -8.08M | -266K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 52.42% | -81.35% | 19.06% | -28.3% | 48.52% | -47.28% | -30.29% | 53.25% | -125.39% | -81.97% | -2936.09% | - |
| EBITDA | -13.83M | -13.69M | -28.79M | -15.88M | -19.61M | -15.25M | -29.67M | -20.16M | -15.49M | -33.12M | -14.7M | -7.17M | -266K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 46.39% | 52.44% | -81.27% | 19.01% | -28.58% | 48.6% | -47.18% | -30.18% | 53.25% | -125.39% | -105.02% | -2594.74% | - |
| D&A (Non-Cash Add-back) | 20K | 19K | 24K | 6K | 20K | 48K | 46K | 17K | 0 | 0 | 0 | 0 | 0 |
| EBIT | -13.54M | -13.71M | -28.81M | -15.89M | -11.78M | -15.28M | -29.72M | -20.18M | -15.49M | -33.12M | -14.7M | -7.17M | -266K |
| Net Interest Income | 467K | 510K | 920K | 461K | -2.19M | 14K | 39K | -22K | -40K | -286K | 114K | -762K | -55K |
| Interest Income | 467K | 510K | 920K | 461K | 0 | 14K | 39K | 0 | 0 | 0 | 114K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 2.19M | 0 | 0 | 22K | 40K | 286K | 0 | 762K | 55K |
| Other Income/Expense | 722K | 735K | 1.22M | 3.42M | 5.66M | 14K | 38K | -1.14M | -43K | -291K | 110K | -953K | -54K |
| Pretax Income | -13.13M | -12.97M | -27.59M | -12.47M | -13.97M | -15.28M | -29.68M | -21.31M | -15.53M | -33.41M | -14.59M | -9.03M | -320K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -13.13M | -12.97M | -27.59M | -12.47M | -13.97M | -15.28M | -29.68M | -21.31M | -15.53M | -33.41M | -14.59M | -9.03M | -320K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 46.54% | 52.98% | -121.27% | 10.72% | 8.62% | 48.5% | -39.25% | -37.24% | 53.53% | -129.09% | -61.55% | -2721.56% | - |
| Net Income (Continuing) | -13.13M | -12.97M | -27.59M | -12.47M | -13.97M | -15.28M | -29.68M | -21.31M | -15.53M | -33.41M | -14.59M | -9.03M | -320K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.70 | -7.35 | -39.16 | -27.06 | -477.84 | -1742.40 | -4831.20 | -10771.20 | -112860.00 | -213180.00 | -106454.37 | -93780.39 | -2300.65 |
| EPS Growth % | 83.69% | 81.23% | -44.72% | 94.34% | 72.58% | 63.93% | 55.15% | 90.46% | 47.06% | -100.25% | -13.51% | -3976.26% | - |
| EPS (Basic) | - | -7.35 | -39.16 | -27.06 | -477.84 | -1742.40 | -4831.20 | -10771.20 | -112860.00 | -213180.00 | -106454.37 | -93780.39 | -2300.65 |
| Diluted Shares Outstanding | 4.86M | 1.77M | 705.19K | 461.01K | 29.25K | 8.77K | 6.14K | 1.98K | 209 | 157 | 140 | 139 | 139 |
| Basic Shares Outstanding | 4.86M | 1.77M | 705.19K | 461.01K | 29.25K | 8.77K | 6.14K | 1.98K | 209 | 157 | 140 | 139 | 139 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liquidity and clinical execution
As indicated by the company's financial filings, MetaVia remains a pre-revenue entity, with zero reported sales across the last ten quarters, underscoring the speculative nature of its current clinical-stage business model and the total absence of commercial traction for its GPR119-targeted therapeutic pipeline.
The lack of revenue generation confirms that the company is entirely dependent on external capital to fund its research initiatives. Investors should monitor the potential for milestone-based inflows, though these remain contingent on successful clinical trial outcomes rather than organic market demand.
Based on reported income statements, MetaVia's cost structure is dominated by R&D expenditures, which peaked at $8.1 million in 2024Q2, reflecting the high variable costs associated with outsourced clinical research and the ongoing development of its cardiometabolic drug candidates.
The fluctuation in R&D spending suggests a project-based cost model that is highly sensitive to the timing of clinical trial phases. Management's ability to control these expenses is critical, as the current burn rate appears to be the primary determinant of the company's remaining operational runway.
According to historical income data, MetaVia exhibits a consistently negative operating margin profile, with operating losses reaching as high as $10.1 million in 2024Q2, demonstrating that the firm has yet to achieve the scale necessary to offset its fixed administrative and research overhead.
The absence of gross profit means that every dollar spent on SG&A and R&D directly exacerbates the net loss position. This structure implies that the company cannot achieve operational leverage until it transitions to a commercial or royalty-based revenue model, which remains a distant prospect.
As reported in financial statements, the company's net loss figures are frequently impacted by non-cash items and stock-based compensation, which, while totaling $111,000 in 2025Q2, highlight the reliance on equity-based financing to sustain operations in the absence of traditional debt or operational cash flow.
The low debt-to-equity ratio may provide a misleading sense of financial health, as the true cost of capital is realized through shareholder dilution. Analysts should focus on the net cash burn from operations to better understand the company's proximity to a potential liquidity crisis.
With cash and equivalents reported at approximately $10.3 million, the company faces significant liquidity pressure, as evidenced by the persistent quarterly net losses that necessitate frequent capital raises to maintain the current pace of clinical development for its MASH and obesity programs.
The reliance on external funding sources creates a binary risk profile where any delay in clinical milestones could severely impair the company's ability to secure further financing. Investors should remain cautious regarding the potential for further dilutive equity offerings in the near term.
Quick answers to the most common questions about buying MTVA stock.
For fiscal year 2025, MetaVia Inc. (MTVA) reported total revenue of $0.0M.
MetaVia Inc. (MTVA) reported a net loss of $13.0M for the fiscal year ending 2025.